Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep1445 | Thyroid (non-cancer) | ECE2017

Theranostic management of medullary thyroid cancer (MTC) with (111In/177Lu) CP04: how close are we to a clinical solution?

Hubalewska-Dydejczyk Alicja , Erba Paola , Decristoforo Clemens , Zaletel Katja , Mikolajczak Renata , Maecke Helmut , Maina-Nock Theodosia , Konijnenberg Mark , Kolenc-Peitl Petra , Trofimiuk-Muldner Malgorzata , Przybylik-Mazurek Elwira , Virgolini Irene , Pawlak Dariusz , de Jong Marion , Froberg Alide C , Rangger Christine , Goebel Georg , Scarpa Lorenza , Skorkiewicz Konrad , Lezaic Luka , Garnuszek Pirotr , Sowa-Staszczak Anna , Nock Berthold A , Bergant Damijan , Rep Sebastijan , Glowa Boguslaw

Effective targeted therapy for advanced endocrine malignancies is a goal of modern endocrinology. We herein present promising results of the first phase of clinical part of European project (Gran-T-MTC) aimed to assess the safety of gastrin analogue CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) i.v. administration in dose (50 μg) useful for translation to 177In-CP04 for PRRT. CP04 has been selected for MTC therapy based on a high CCK-2 receptor...